Advertisement
     

Main Menu
Stock news
Forex news
Forex Charts
Live Market News
Economic Calendar
Links
Forum
About
User Menu
My Favourites
Bookmark Us
 
 
Login Form





Lost Password?
No account yet? Register
StockTopsites.com
FXtopsites.com
TOP 100 INVESTING SITES
TOP 100 FINANCIAL SITES
TOP 100 FOREX SITES

FeedTheBull - Top Stock market and Finance Sites


Merck & Company Inc. - MRK
 
  

 
 

Yahoo! Finance: MRK News

Latest Financial News for MERCK CO INC

Yahoo! Finance

Yahoo! Finance: MRK Financial Blogs

Latest Financial Financial Blogs for MERCK CO INC

Yahoo! Finance

MSN Money News - MRK

News about Merck & Co Inc

  • Sector Snap: Obesity drug developers

    (Thursday, November 20, 2008 12:03 PM)

    NEW YORK (AP) - Obesity drug developers may have trouble getting drugs reimbursed by private and government health plans, though physicians will likely be enthusiastic about the treatments, said Lazard Capital Markets.

  • Holder Has Corporate-Crime Experience

    (Thursday, November 20, 2008 11:56 AM)

  • Early Glance: Pharmaceuticals companies

    (Thursday, November 20, 2008 10:39 AM)

    NEW YORK (AP) - Shares of some top pharmaceuticals companies are mixed at 10 a.m.:

  • Netherlands selects Glaxo cervical cancer vaccine

    (Thursday, November 20, 2008 8:42 AM)

    LONDON (AP) - British drug maker GlaxoSmithKline PLC said Thursday that the Dutch government has selected its cervical cancer vaccine Cervarix for a nationwide vaccination program.

  • How to Become an Accidental Billionaire

    (Thursday, November 20, 2008 6:23 AM)

    Read about those who did it, and how you can do it, too.

  • How to Become an Accidental Billionaire

    (Thursday, November 20, 2008 4:10 AM)

    Read about those who did it, and how you can do it, too.

  • Correction: Merck ratings

    (Wednesday, November 19, 2008 4:44 PM)

    NEW YORK (AP) - In a Nov. 17 story about Merck and Co., The Associated Press erroneously reported the results of a clinical trial involving Merck's cholesterol drug Vytorin. The trial showed that Vytorin was no better than a generic drug at preventing arterial plaque buildup. It did not show that the drugs were equally effective in reducing cholesterol.

MRK - News and Analysis from Seeking Alpha

'MRK' Tag RSS Syndication from SeekingAlpha.com

  • Pharmas and Biotech: Vying for Outsize Insulin Profits

    (Thu, 20 Nov 2008 14:09:21 -0500)

    Nektar Therapeutics (NKTR) has been struggling since 2007, when Pfizer (PFE) discontinued selling Nektar's Exubera inhaled insulin because of disappointing sales. Then Novartis (NVS) stepped in and bought Nektar’s pulmonary medicine delivery systems. It clearly sees profit where Pfizer didn’t. Nektar jettisoned its insulin inhaler, but still happily reported on its Q308 conference call that it had


    Hickey and Walters (Bespoke) submit:

    The Dow Jones Industrial Average is still about 15% above the bear market closing low on October 9th, 2002, but half of the index's current members are now down since then.  Below we highlight each Dow member's percentage change since 10/9/02.  As shown, McDonald's (MCD) is up the most at 241%, followed by Hewlett-Packard (HPQ), Exxon Mobil (XOM), Chevron (CVX), and Caterpillar (CAT).  Surprisingly, financial giant JP Morgan (JPM) is also one of the best performers with a gain of 108%.

    General Motors (GM) is, not surprisingly, down the most since...

  • Merck Rolls the Dice on New Januvia Study

    (Sun, 16 Nov 2008 02:35:12 -0500)

    Mike Huckman submits:

    The drug company that got into so much trouble when it uncovered and/or disclosed a cardiovascular side-effect of a popular painkiller (Vioxx) is launching a huge study to see if an up-and-coming diabetes drug is also bad for the heart.

    In a research note to clients on Friday, Deutsche Bank's Barbara Ryan unearthed this posting that went up Thursday on the government's web site for clinical trials.


    Complete Story »

  • SEAS Prove Calming for Schering-Plough

    (Thu, 13 Nov 2008 13:30:32 -0500)

    Mike Huckman submits:

    On a very weak big pharma tape, shares of Schering-Plough (SGP) started to rally Wednesday morning. As I wrote this, the only other stock in the sector that was trading higher—albeit fractionally—is Wyeth (WYE), because Goldman Sachs added it to its "Conviction Buy List." (For those unfamiliar with it, the CBL means the analyst is pounding the table...

  • Top Global Dividend Stocks

    (Wed, 12 Nov 2008 09:03:46 -0500)

    David Hunkar submits:

    The Dow Jones STOXX Global Select Dividend 100 Index tracks the high-dividend-yielding companies in the Dow Jones STOXX Global 1800 Index that includes the Americas,Europe and Asia-Pacific. The 100 components in the index contains 40 stocks for the Americas and 30 each for Europe and Asia-Pacific.

    The Dow Jones STOXX Global Select Dividend 100 Index Components:


    Complete Story »

  • Dow Price Targets

    (Tue, 04 Nov 2008 17:17:32 -0500)

    Hickey and Walters (Bespoke) submit:

    Below we highlight consensus analyst price targets for the 30 stocks that make up the Dow Jones Industrial Average. As shown, Alcoa's (AA) price target is currently the highest above its actual price at 52%. AA is trailed by [[HPQ]] and [[INTC]] with price targets 40% above current levels.

    General Motors (GM) is the only stock in the index with a price target that is lower than its actual price. With the record of analysts these days, price targets should be taken with a grain of salt, but we thought...

  • Cramer's Lightning Round - (10/31/08) Safe as Weyerhaeuser

    (Mon, 03 Nov 2008 06:21:16 -0500)

    Stocks discussed in the lightning round session of Jim Cramer’s Mad Money TV program, Friday October 31.

    Bullish calls:

    Duke Energy(DUK), Con Edison (ED)


    Complete Story »

  • Merck Goes Back to School to Push HPV Vaccination

    (Fri, 31 Oct 2008 14:28:58 -0400)

    Mike Huckman submits:

    As a reporter, you never know when or where you might stumble on a story—or at least a blog entry.

    There I was Wednesday guest lecturing for an old friend's TV-news production class at my alma mater. So, while at the USC Annenberg School of Communications, I picked up a copy of the "Daily Trojan" just to check out the student paper I once had to work at for a semester back in the day.


    Complete Story »

  • Cramer's Mad Money - Does the Rate Cut Matter? (10/29/08)

    (Thu, 30 Oct 2008 07:36:02 -0400)

    Stocks discussed in the in-depth session of Jim Cramer’s Mad Money TV program, Wednesday October 29.

    Does the Rate Cut Matter?  Verizon (VZ), Merck (MRK), BB&T (BBT), Watsco (WSO), Eaton (ETN), Caterpillar (CAT)


    Complete Story »

  • Merck Continues to Thin Out

    (Thu, 23 Oct 2008 13:46:33 -0400)

    derek loweDerek Lowe submits:

    As everyone knows, Merck (MRK) announced some big job cuts Wednesday – 7,200 positions, around 10% of the work force. It’s worth looking at the details of these, because they differ a bit from what’s been going on at some other companies.

    For one thing, the company doesn’t seem to be exiting any one therapeutic area, as Pfizer (PFE) has, or rearranging their whole R&D structure the way [[GSK]] is doing. Merck just seems to be thinning things out across the whole organization. And that...




Investor Clicks Financial Advertising
Investor Clicks Financial Advertising

News for Merck & Co., Inc. - Google Finance

News for Merck & Co., Inc. - Google Finance

News for Merck & Co., Inc. - Google Finance

MarketWatch.com - All MarketWatch News - MRK

MarketWatch, a leading publisher of business and financial news, offers users up-to-the minute news, investment tools, and subscription products.

MarketWatch.com - All MarketWatch News - MRK

  • Fitch lowers Merck rating outlook to negative from stable

    (Mon, 17 Nov 2008 15:52:32 -0500)

    SAN FRANCISCO (MarketWatch) -- Fitch Ratings said Monday it lowered the ratings outlook for Merck & Co. to negative from stable because top-selling drugs will lose patent protection over the next few years. Fitch has a AA- rating on Merck. About $6.93 billion in debt is affected by the ratings. "Fitch's outlook revision reflects an estimate of flat- to slightly declining revenues over the long term, as potential commercialization of the R&D pipeline will not fully offset declines due to the maturing drug product portfolio, with the worst effect on revenues in 2010, and lessened impacts in 2012 and...

  • Fitch lowers Merck rating outlook to negative from stable

    (Mon, 17 Nov 2008 15:46:46 -0500)

  • Study shows Crestor cuts heart-attack risk, AstraZeneca says

    (Mon, 10 Nov 2008 06:13:00 -0500)

    AstraZeneca says its Crestor anti-cholesterol drug has been shown to reduce heart-attack risk for people without high cholesterol but who have elevated levels of a protein linked to artery inflammation.

  • J&J, Merck recall Mylicon drops on metal fragment risk

    (Mon, 10 Nov 2008 15:19:36 -0500)

    SAN FRANCISCO (MarketWatch) -- Johnson & Johnson-Merck Consumer Pharmaceuticals Co., a joint venture between Johnson & Johnson Inc. and Merck & Co. , said Monday it is recalling lots of its Mylicon antigas treatment for infants because metal fragments may be in the bottles. The recall affects two lots of the product, or about 12,000 bottles, that were distributed after Oct. 5.

  • J&J, Merck recall Mylicon drops on metal fragment risk

    (Mon, 10 Nov 2008 15:13:26 -0500)

  • Merck says it will stay in heart research

    (Sat, 08 Nov 2008 08:00:00 -0500)

  • Pfizer stops development of anti-obesity drug

    (Wed, 05 Nov 2008 17:22:25 -0500)

    WASHINGTON (MarketWatch) -- Pfizer Inc. became the most recent company Wednesday to end development of an anti-obesity compound that falls into the same class of other drugs linked to psychiatric side effects. Pfizer, New York, cited "changing regulatory perspectives" and likely tougher Food and Drug Administration requirements for approval in its decision to stop development of the compound referred to as CP-945,598. The drug falls into the same class of medicines as Sanofi Aventis SA's rimonabant, which had been sold under the brand name Acomplia in Europe.

  • Biotech Stocks: Drug stocks slide day after U.S. election

    (Wed, 05 Nov 2008 15:22:00 -0500)

    Drug stocks slide the day after Americans elected Democratic candidate Barack Obama as their 44th president.

  • Biotech Stocks: Drug stocks rocket with broader market rally

    (Tue, 28 Oct 2008 17:39:00 -0500)

    Drug stocks rally as the broader market warms on hopes that the Federal Reserve will soon move to further lower interest rates.

  • Biotech Stocks: Drug stocks mixed in afternoon trading

    (Mon, 27 Oct 2008 15:17:00 -0500)

    Drug stocks slide with the broader U.S. market early Monday as investors worldwide continue to sell amid fears a global recession is taking hold.



Add as favourites (0) | Quote this article on your site

Be first to comment this article

Only registered users can write comments.
Please login or register.

MRK 



Reddit!Del.icio.us!Google!Facebook!Slashdot!Netscape!Technorati!StumbleUpon!Newsvine!Furl!Yahoo!Ma.gnolia!Free social bookmarking plugins and extensions for Joomla! websites!
 

The Financial Ad Trader
The Financial Ad Trader - banner exchange
Member Of Candlestick Shop Banner Exchange

Stock Market News
Popular Stocks
Random Stocks